Oct 2026· Journal of Medicinal Chemistry· 0 citations· 48 references
TL;DR
Overall, compound 15 represents a promising BCL6 PROTAC degrader for DLBCL, which induced rapid and efficient BCL6 degradation in OCI-LY1 cells and displayed potent antiproliferative activity in BCL6-dependent DLBCL cells.
Abstract
B-cell lymphoma 6 (BCL6) is a key transcriptional repressor involved in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). In this study, scaffold hopping of BI-3802 led to compound 1, a new tricyclic BCL6-targeting ligand. Further optimization of linker architecture and CRBN-recruiting motifs led to compound 15, a potent BCL6 PROTAC degrader, which induced rapid and efficient BCL6 degradation in OCI-LY1 cells (DC50 = 5.32 nM) and displayed potent antiproliferative activity in BCL6-dependent DLBCL cells (IC50 = 3.2 nM). BCL6 degradation was CRBN- and proteasome-dependent and was accompanied by G1-phase arrest and increased p21 and p27 expression. Oral administration of 15 inhibited tumor growth in an OCI-LY1 xenograft model (TGI = 84% at 20 mg/kg) and reduced tumor BCL6 and Ki67 levels without appreciable body-weight loss or overt major-organ histopathology. Overall, compound 15 represents a promising BCL6 PROTAC degrader for DLBCL.
A formal synthesis of cortistatin A, a marine-derived steroidal alkaloid with potent anti-angiogenic and antileukemic activities, was achieved via a unique synthetic strategy that leveraged a late-stage SmI2-mediated oxa-bridge translocation. The de novo–synthesized simplified analog CA411 was evaluated across 38 cell...
Wen-Jun Wang, Nan Zhang, Bai-Cheng Chen et al.· Science Advances· 0 citations
The B-cell lymphoma 3 protein (BCL3) is a transcriptional facilitator protein and anti-cancer drug target driving intracellular cancer signalling pathways including NF-κB (advanced breast) and Wnt-β-catenin (colorectal). BCL3 governs pro-oncogenic processes such as tumour initiation, metastasis, and therapy resistance....
A. D. Westwell, D. Ružić, T. Elstow et al.· Zbornik radova· 0 citations
Histone deacetylase 3 (HDAC3) is an important therapeutic target in cancer, yet selective HDAC3 degraders remain limited. In this study, we report the development of novel class I HDAC degraders derived from the HDAC3-preferential inhibitor FL-007. Two linker exit vectors were investigated, leading to the identificat...
Stephan Lepper, Lukas Biermann, Fabian B. Kraft et al.· Journal of Medicinal Chemist...· 0 citations
Findings identify UMS as a candidate DDI2/NRF1-axis modulator that potentiates BTZ-induced cytotoxicity and delays functional proteasome recovery in BTZ-resistant malignant lymphoma cells.
Atsumi Ota, Sota Maruyama, Yudai Kudo et al.· Biochimica et biophysica act...· 0 citations
COP9 signalosome subunit 5 (CSN5) exerts critical deneddylase activity and is frequently overexpressed in triple-negative breast cancer (TNBC), representing a compelling antitumour target. However, to date, only a limited number of inhibitors targeting CSN5 have been reported, and none of them have advanced into clinic...
Zhi-Wen Yang, Wen-Yi Liu, Yi-Chun Miao et al.· European journal of medicina...· 0 citations
PKMYT1 is a critical regulator of the cell cycle and has emerged as a promising synthetic lethal target for CCNE1-amplified cancers. In this study, we report the design, synthesis, and biological evaluation of a novel series of 4-aminoquinazoline-based PKMYT1 inhibitors. A hydrogen bond donor-to-acceptor conversion str...
Hai-Xiang Qi, Rui Lu, Yi-Fei Zhu et al.· Journal of Medicinal Chemist...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
